*To the Editor*:

On 11 March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a pandemic. As of 22 April, more than 2.4 million cases have been confirmed worldwide \[[@C1]\]. In light of the widely documented lung injuries related to COVID-19 \[[@C2], [@C3]\], concerns have been raised regarding the assessment of lung injury for discharged patients. A recent report portrayed that discharged patients with COVID-19 pneumonia still have residual abnormalities in chest computed tomography (CT) scans, with ground-glass opacity as the most common pattern \[[@C4]\]. Persistent impairment of pulmonary function and exercise capacity have been known to last for months or even years \[[@C5]--[@C8]\] in the recovered survivors from other coronavirus pneumonia (severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)). However, until now, there is no report in regard to pulmonary function in discharged COVID-19 survivors. This article aims to describe the characteristics of pulmonary function in these subjects.

We recruited laboratory-confirmed noncritical COVID-19 cases, from 5 February to 17 March 2020, from admitted patients. According to the WHO interim guidance \[[@C9]\] and the guidance from China \[[@C10]\], disease severity was categorised as mild illness (mild symptoms without radiographic appearance of pneumonia), pneumonia (having symptoms and the radiographic evidence of pneumonia, with no requirement for supplemental oxygen), severe pneumonia (having pneumonia, including one of the following: respiratory rate \>30 breaths·min^−1^; severe respiratory distress; or oxygen saturation measured by pulse oximetry (*S*~pO~2~~) ≤93% on room air at rest), and critical cases (*e.g.* respiratory failure requiring mechanical ventilation, septic shock, other organ failure occurrence or admission into the intensive care unit). Critical cases were excluded from our study. Spirometry and pulmonary diffusion capacity tests (Quark PFT; Cosmed, Rome, Italy) were performed following the American Thoracic Society/European Respiratory Society guidelines on the day of or 1 day before discharge. To minimise cross-infections, diffusing capacity of the lung for carbon monoxide (*D*~LCO~) was measured by the single-breath method. Written informed consent was obtained from all patients, and the study was approved by the ethics committee of The Guangzhou Eighth People\'s Hospital.

110 discharged cases were recruited, which included 24 cases of mild illness, 67 cases of pneumonia and 19 cases of severe pneumonia ([table 1](#TB1){ref-type="table"}). The mean age of these cases was 49.1 years and 55 of them were females. 44 patients (40%) had at least one underlying comorbidity, of which 23.6% had hypertension and 8.2% had diabetes. Only three patients (2.7%) were reported as having chronic respiratory diseases (one patient with asthma, one with chronic bronchitis and one with bronchiectasis). No significant differences were found among the three groups of cases in relation to sex, smoking status, underlying disease and body mass index. The mean±[sd]{.smallcaps} duration from onset of disease to pulmonary function test was 20±6 days in cases with mild illness, 29±8 days in cases with pneumonia and 34±7 days in cases that presented severe pneumonia. On the day of discharge, the *S*~pO~2~~ on room air at rest was normal in all subjects and no significant difference was found among the different groups (all p\>0.05).

###### 

Demographics and pulmonary function characteristics of discharged patients with COVID-19

                                                **Total**    **Mild illness**   **Pneumonia**    **Severe pneumonia**    **p-value**
  ------------------------------------------- ------------- ------------------ --------------- ------------------------ -------------
  **Patients**                                     110              24               67                   19            
  **Age years**                                 49.1±14.0       46.8±15.6         47.9±13.7        56.5±11.0\*^,\#^         0.04
  **Female**                                    55 (50.0)       13 (54.2)         36 (53.7)            6 (31.6)             0.21
  **Smoker**                                    13 (11.8)        4 (16.7)         7 (10.4)             2 (10.5)             0.707
  **BMI kg·m^−2^**                              23.5±3.0         23.1±2.8         23.6±3.2             23.5±2.7             0.794
  **Duration from onset to discharge days**       27±9             20±6           29±8\*\*          34±7\*\*^,\#^          \<0.001
  **Underlying disease**                        44 (40.0)       10 (41.7)         25 (37.3)            9 (47.4)             0.719
   Lung disease                                  3 (2.7)          0 (0)            3 (4.5)              0 (0)                 1
   Heart disease                                 3 (2.7)         1 (4.2)           2 (3.0)              0 (0)                 1
   Hypertension                                 26 (23.6)        6 (25.0)         15 (22.4)            5 (26.3)             0.924
   Cerebrovascular disease                       3 (2.7)          0 (0)            2 (3.0)             1 (5.3)              0.532
   Diabetes                                      9 (8.2)         1 (4.2)           6 (9.0)             2 (10.5)             0.702
   Liver disease                                 6 (5.5)         2 (8.3)           3 (4.5)             1 (5.3)              0.837
   Kidney disease                                2 (1.8)         1 (4.2)           1 (1.5)              0 (0)               0.631
   Solid tumour                                  1 (0.9)          0 (0)             0 (0)              1 (5.3)              0.173
  ***S*~pO~2~~ on discharge %**                 98.7±1.0         98.6±1.2         98.7±1.0             98.5±1.0             0.73
  **Spirometry**                                                                                                        
   FVC % pred                                  93.59±12.25     94.06±10.48       94.12±12.31         91.12±14.30            0.632
   FVC \<80% pred                               10 (9.09)       3 (12.50)         5 (7.46)            2 (10.53)             0.644
   FEV~1~ % pred                               92.70±11.57     94.26±11.00       92.59±11.87         91.12±11.58            0.676
   FEV~1~ \<80% pred                           15 (13.64)       4 (16.67)         9 (13.43)           2 (10.53)             0.857
   FEV~1~/FVC %                                80.70±5.81       81.84±5.48       80.39±6.12           80.19±5.15            0.509
   FEV~1~/FVC \<70%                             5 (4.55)          0 (0)           5 (7.46)              0 (0)               0.349
   MMEF % pred                                 97.40±26.23     99.77±28.17       96.59±26.51         96.14±23.82            0.879
   MMEF \<65% pred^¶^                           7 (6.42)         1 (4.17)         6 (9.09)              0 (0)               0.551
   FEF~50%~ % pred                             94.74±26.11     97.47±25.48       94.09±26.80         93.53±25.56            0.845
   FEF~50%~ \<65% pred^¶^                      12 (11.01)        2 (8.33)         8 (12.12)           2 (10.53)               1
   FEF~75%~ % pred                             96.10±32.56     102.23±40.20      95.02±30.89         92.08±27.92            0.549
   FEF~75%~ \<65% pred^¶^                      12 (11.01)       3 (12.50)         4 (6.06)          5 (26.32)^\#^           0.035
  **Diffusion capacity**                                                                                                
   *D*~LCO~ % pred                             78.18±14.29     84.70±13.88       79.76±11.99    64.79±14.35\*\*^,\#\#^     \<0.001
   *D*~LCO~ \<80% pred                         51 (47.22)       7 (30.43)        28 (42.42)     16 (84.21)\*\*^,\#\#^       0.001
   *D*~LCO~/*V*~A~ % pred                      92.09±16.68     99.35±18.25       92.30±15.70     82.58±13.91\*\*^,\#^       0.004
   *D*~LCO~/*V*~A~ \<80% pred                  29 (26.85)       3 (13.04)        18 (27.27)           8 (42.11)             0.09
  **Lung volume**                                                                                                       
   TLC % pred                                  86.32±11.32     87.13±10.43       88.11±10.72     79.16±12.13\*^,\#\#^       0.008
   TLC \<80% pred                              27 (25.00)       4 (17.39)        14 (21.21)        9 (47.37)\*^,\#^         0.049
   RV % pred                                   86.83±19.37     87.17±16.88       89.79±19.21      76.16±19.96^\#\#^         0.024
   RV \<65% pred                                10 (9.26)        2 (8.70)         3 (4.55)          5 (26.32)^\#^           0.021
   RV/TLC % pred                               96.99±16.72     98.00±14.93       98.53±17.55         90.42±14.86            0.168

Data are presented as n, mean±[sd]{.smallcaps} or n (%), unless otherwise stated. Comparisons between continuous variables were performed with one-way ANOVA. Chi-squared test and Fisher\'s exact test were applied to categorical variables as appropriate. BMI: body mass index; *S*~pO~2~~: oxygen saturation measured by pulse oximetry; FVC: forced vital capacity; FEV~1~: forced expiratory volume in 1 s; MMEF: maximal mid-expiratory flow; FEF~50%~: forced expiratory flow at 50% of FVC; FEF~75%~: forced expiratory flow at 75% of FVC; *D*~LCO~: diffusing capacity of the lung for carbon monoxide; *D*~LCO~/*V*~A~: *D*~LCO~ corrected for alveolar volume; TLC: total lung capacity; RV: residual volume. \*: p\<0.05 *versus* mild illness; \*\*: p\<0.01 *versus* mild illness; ^\#^: p\<0.05 *versus* pneumonia; ^\#\#^: p\<0.01 *versus* pneumonia; ^¶^: at least two of these \<65% pred defined patients with small airway function anomalies.

Spirometry was uneventfully completed in all patients, except for two failed diffusion capacity tests. Anomalies were noted in *D*~LCO~ % predicted in 51 cases (47.2%), total lung capacity (TLC) % pred in 27 (25.0%), forced expiratory volume in 1 s (FEV~1~) % pred in 15 (13.6%), forced vital capacity (FVC) % pred in 10 (9.1%), FEV~1~/FVC in five (4.5%), and small airway function in eight (7.3%). [Table 1](#TB1){ref-type="table"} shows a significant difference in impaired diffusing capacity among the different groups of severity, which accounted for 30.4% in mild illness, 42.4% in pneumonia and 84.2% in severe pneumonia, respectively (p\<0.05). This trend of the gradual decrease in level of *D*~LCO~ among patients was identical with the varying degree of severity. For about half (25 out of 51) of the *D*~LCO~-impaired patients, the *D*~LCO~ corrected for alveolar volume (*D*~LCO~/*V*~A~) was still within the normal range, which might indicate that the *D*~LCO~ decrease was more than the *D*~LCO~/*V*~A~ decrease, in recovered subjects. The value of TLC % pred in severe pneumonia cases was much less than that of pneumonia or mild illness cases, suggesting higher impairment of lung volume in severe cases. There was no significant difference among the discharged survivors with different severity in regard to other ventilatory defects (*e.g.* FEV~1~, FVC, FEV~1~/FVC).

Recent studies reveal that the lung is the organ most affected by COVID-19 \[[@C2], [@C3]\], with pathologies that include diffuse alveolar epithelium destruction, capillary damage/bleeding, hyaline membrane formation, alveolar septal fibrous proliferation, and pulmonary consolidation. Previous studies have demonstrated that recovered patients with coronavirus pneumonia can be left with damaged lungs. Impaired lung function was common and could last for months or even years. In the follow-up studies lasting 0.5--2 years in rehabilitating SARS patients \[[@C5]--[@C7]\], impaired *D*~LCO~ was the most common abnormality, ranging from 15.5% to 43.6%, followed by defective TLC, ranging from 5.2% to 10.9%. P[ark]{.smallcaps} *et al.* \[[@C8]\] showed that 37% of MERS survivors still presented with an impairment of *D*~LCO~, but normal TLC, at 12 months. Our study seems to be more consistent with the findings in SARS. Interestingly, in our study, the greater decline in *D*~LCO~ *versus D*~LCO~/*V*~A~ suggests that the diffusion membrane may be more causative of the pulmonary dysfunction compared to lowered lung volume. The low proportion and severity of small airway dysfunction in our cohort also suggests that COVID-19 is more likely associated with diffuse lung epithelial damage and small airway congestion. when evaluating lung fibrotic changes in SARS, the dynamic *D*~LCO~ scores were found to be more sensitive than high-resolution CT \[[@C11]\]. Whether survivors of COVID-19 with impairment of *D*~LCO~ or residual abnormalities on chest CT will develop pulmonary fibrosis requires further investigation.

There are limitations in our study. First, the lack of baseline pulmonary function test results prior to the illness make it difficult to make a comparison with the results after the illness. There were only a minority of patients with chronic respiratory disease, so it should be acceptable to speculate that the basic lung function in the majority of patients would be normal. The interpretation regarding the impact of COVID-19 on lung function remains valid. Secondly, the association between CT images and the lung function parameters was not analysed in our study. Finally, this cross-sectional analysis only provides a short follow-up, and the long-term dynamic variation of lung function after hospital discharge still requires further investigation.

In conclusion, our study reveals that, in discharged survivors with COVID-19, impairment of diffusion capacity is the most common abnormality of lung function, followed by restrictive ventilatory defects, which are both associated with the severity of the disease. Pulmonary function tests (not only spirometry but also diffusion capacity) should be considered in routine clinical follow-up for certain recovered survivors, especially in severe cases. Subsequent pulmonary rehabilitation might be considered as an optional strategy. Long-term studies are needed to address whether these deficits are persistent.
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